For this glp-1 providers & telehealth guide, the useful starting point is not whether the internet is excited about it. It is whether the evidence, safety limits, prescription pathway, and follow-up plan are strong enough to support a real patient decision.
Last March, a friend of mine in Phoenix texted me a screenshot of an Instagram ad. The ad promised tirzepatide for $149 a month, “no appointment necessary, ships in 48 hours.” She’d already entered her credit card number. I asked her one question: “Did a clinician review anything, or did you just fill out a form?” Silence. Then: “It was like five checkboxes.” She cancelled before anything shipped, but the experience stuck with me. Because the ad wasn’t some obvious scam. It looked clean, professional, medically branded. And that’s the problem.
The short answer to “how do I pick a GLP-1 telehealth provider” is boring but reliable: a reputable one runs a real licensed-clinician evaluation, discloses its pharmacy partners, publishes transparent pricing, and keeps clinical support accessible after the prescription goes out. If you got a prescription without anyone actually reviewing your case, that’s not efficiency. That’s a red flag dressed up as convenience.
The Post-Shortage Landscape Is Messier Than It Looks
Between 2022 and 2024, tirzepatide and semaglutide shortages created a vacuum. Telehealth platforms rushed in to fill it, and many of them were genuinely good. But plenty weren’t. The range you’ll encounter today spans from clinically serious operations with credentialed prescribers and disclosed pharmacy relationships all the way down to what are essentially digital prescription mills running on form-only intakes.
The tricky part: the bad actors have gotten better at looking like the good ones. Same color palettes, same stock photos of stethoscopes, same “clinician-backed” language in the footer. So you need a checklist that maps to actual operational and clinical quality signals, not to marketing polish.
What the Visit Should Actually Involve
A real clinical evaluation includes medical history review, current medication list, BMI documentation, and contraindication screening. This can happen asynchronously (you don’t necessarily need a live video call), but a licensed clinician has to review the case before any prescription is generated. That’s the key sequence. Evaluation first, then prescription. Not the other way around.
Form-only intakes that auto-generate prescriptions skip the part that matters. Think of it like a pilot skipping the pre-flight checklist because the sky looks clear. Most of the time nothing goes wrong. But the one time it does, you really wish someone had checked the instruments.
Beyond the initial visit, continuity matters. Patients who interact with the same prescriber across visits tend to experience fewer dose-pacing errors and better side-effect management. Services that rotate clinicians can still work, but they depend on strong documentation handoffs, and in practice, those handoffs are often where things get dropped.
The Checklist: What You Can Actually Verify
State medical licensure. The names and licenses of prescribing clinicians should be discoverable. You can check them against state medical board databases yourself. Anonymous prescriber operations are a meaningful warning sign.
Pharmacy disclosure. Quality providers communicate whether they work with 503A (patient-specific) or 503B (outsourcing facility) pharmacies. Where state regulations permit, the pharmacy name should be available. You can verify standing against state pharmacy board records.
Pricing transparency. Monthly costs should be itemized. Consultation fees, medication fees, and renewal fees should be separable, not bundled into a single opaque number. Cancellation and refund policies deserve reading before you pay, not after.
Clinical access and response time. How fast does the provider respond to side-effect questions? One business day for clinical issues, minutes to hours for routine messages, is a reasonable benchmark. Script-only services that vanish after the first shipment are running a thin model.
Lab monitoring guidance. Operations that prescribe without referencing monitoring labs are cutting corners the literature doesn’t support. If a provider never mentions labs, ask why.
Data privacy. HIPAA compliance is the floor, not the ceiling. Confirm the platform handles records under HIPAA protections and that third-party data sharing is limited and disclosed.
Offboarding. Before you sign up, find out what happens if you cancel or move. What becomes of your medical record, your prescription, your refill schedule? Reputable services spell this out in the patient agreement.
What Things Cost Right Now
Branded Zepbound retails at roughly $1,059 per month without insurance. Eli Lilly’s LillyDirect self-pay vial program offers eligible patients access at $499 monthly for certain doses, with eligibility criteria attached.
Compounded tirzepatide through reputable telehealth pathways typically lands between $197 and $397 per month depending on dose tier, term commitment, and provider. This is all cash-pay. Insurance generally does not cover compounded preparations because they are not FDA-approved finished drugs.
| Format | Typical Monthly Cash Range | Notes | |—|—|—| | Branded Zepbound (cash) | $1,059 retail; $499 via LillyDirect self-pay vial program | Manufacturer self-pay vial pathway requires meeting criteria | | Branded Mounjaro (commercial copay card) | $25 to $573 with eligibility | Off-label for weight loss not covered | | Compounded tirzepatide (503A) | $197 to $397 | Patient-specific, prescription required, varies by dose | | Compounded tirzepatide (503B office stock) | Varies by clinic markup | Clinic-administered or clinic-distributed |
HSA and FSA funds are typically eligible for prescription compounded medications with appropriate documentation. Keep itemized receipts.
Quarterly or six-month commitment terms often bring the per-month price down, but auto-renewal clauses deserve scrutiny. Some services lock patients into multi-month commitments with limited refunds. Others offer pro-rated cancellation. The gap between these two models is significant.
Branded vs. Compounded: Same Molecule, Different Oversight
The active ingredient (tirzepatide) is identical. The differences sit at the manufacturing, regulatory oversight, packaging, and price level.
Branded Zepbound and Mounjaro are FDA-approved finished drugs manufactured by Eli Lilly under cGMP standards, with established labeling and post-marketing surveillance. Compounded preparations come from 503A pharmacies (patient-specific) or 503B outsourcing facilities (cGMP-inspected, may produce office stock). Compounded preparations are not FDA-evaluated for safety, efficacy, or quality the way branded products are. The compounding regulatory framework relies on state pharmacy board oversight, federal section 503A and 503B requirements, and individual prescriber clinical judgment.
That’s a real tradeoff, not a trivial one. My honest take: compounded tirzepatide from a well-credentialed pharmacy with proper clinical oversight is a reasonable option for patients priced out of branded products, but it is not the same thing as branded product, and providers who pretend the distinction doesn’t exist are not being straight with you.
A more detailed treatment of provider evaluation criteria, dosing protocols, side-effect management, and the regulatory framework is available in this glp-1 providers & telehealth guide. If you’re actively comparing providers, reading the clinical references alongside marketing material is worth the time.
When to Contact a Clinician
Immediately: Severe abdominal pain (especially radiating to the back), signs of dehydration, vision changes in diabetic patients, signs of allergic reaction.
Within days: Side effects substantially limiting daily function, persistent vomiting beyond 48 hours, intolerable reflux not responding to positioning and timing changes.
Routine visit: Dose-pacing questions, plateau review, lab monitoring schedule, long-term planning.
A licensed clinician should be involved in any decision to initiate, modify, or discontinue therapy. Full stop.
Frequently Asked Questions
How do I evaluate a GLP-1 telehealth provider?
Look for state medical licensure transparency, named clinicians (not anonymous staff), a real telehealth visit (not a form-only intake), 503A or 503B pharmacy disclosure, a clear refund policy, and accessible clinical support. “One-click prescription” models without genuine clinician evaluation correlate with worse patient outcomes.
Is the consultation a real visit?
Reputable providers run an asynchronous or synchronous evaluation by a licensed clinician who reviews medical history, asks targeted questions, and screens for contraindications. A pure form-fill without clinician review is not a real evaluation, regardless of what the marketing calls it.
Are the pharmacies disclosed?
Quality providers disclose whether they work with 503A or 503B pharmacies, the pharmacy name where regulations permit, and any third-party testing performed on their preparations.
What about state availability?
Telehealth GLP-1 services typically operate in 40 to 49 states, with variation driven by state medical board rules and pharmacy distribution agreements. Always confirm the service operates in your state before entering payment information.
How are prescriptions refilled?
Refills usually follow a monthly or quarterly cadence with periodic check-ins from the clinical team. Lab monitoring recommendations vary by provider, and reputable services build in scheduled clinical contact rather than running refills on autopilot.
What if I have a side effect?
Reputable providers maintain accessible clinical contact for side-effect questions and dose adjustments. Response time and clinician access during business hours are the practical differentiators between patient-supportive and script-only operations.
Can I use HSA or FSA funds?
In most cases, yes. Prescription compounded medications are typically HSA/FSA eligible with appropriate documentation. Retain itemized receipts showing the prescription nature of the charge.
Important regulatory note. Compounded tirzepatide is not FDA-approved. It is prepared by licensed 503A or 503B pharmacies for individual patients based on a prescriber’s clinical judgment. Compounded preparations are not evaluated by the FDA for safety, efficacy, or quality the way branded products are. Research suggests outcomes vary between patients, and any decision to begin, modify, or discontinue therapy should occur in coordination with a licensed clinician who can review your medical history, current medications, and laboratory values.
